Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature
References (71)
- et al.
Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology
Blood
(2002) - et al.
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer
Eur J Cancer
(2004) - et al.
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Control Clin Trials
(1996) - et al.
Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales
J Pain Symptom Manage
(2002) - et al.
Meta-analysis in clinical trials
Control Clin Trials
(1986) Erythropoietin for anaemia in cancer patients
Eur J Cancer
(1993)- et al.
Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response
Blood
(1995) - et al.
Erythropoietin increases hemoglobin during radiation thera py for cervical cancer
Int J Radiat Oncol Biol Phys
(1994) - et al.
Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial
J Pain Symptom Manage
(2003) - et al.
Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: A prospective, randomized, double-blind placebo-controlled multicenter study
Gynecol Oncol
(1997)
Recombinant human erythropoietin in the treatment of chemotherapy induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study
Ann Oncol.
Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: A randomized, double-blind, placebo-controlled trial
J Pediatr.
Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinumbased chemotherapy: Results of a multicenter randomised controlled trial
Eur J Cancer
Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin
Eur J Cancer
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial
Lancet
Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy
Clin Breast Cancer
Health, economic, and qualityof-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, controlled trial
Blood
Prediction of response to erythropoietin treatment in chronic anemia of cancer
Blood
Clinical practice guidelines in oncology: Cancer and treatment-related anemia
Erythropoietin for patients with malignant disease
Cochrane Database Syst Rev
Role of erythropoietin in the management of cancer patients with nonhaematologic malignancies receiving chemotherapy
Curr Oncol
Oncologic Drugs Advisory Committee
Systematic reviews: Synthesis of best evidence for clinical decisions
Ann Intern Med
Aranesp [package insert]
Procrit [package insert]
Statistical aspects of the analysis of data from retrospective studies of disease
J Natl Cancer Inst
Statistical Methods for Rates and Proportions
Meta-Analysis, Decision Analysis, Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine
Statistical Methods for Meta-analysis
Recombinant human erythropoietin for platinum-based chemotherapyinduced anaemia: A single-centre randomised study
J Balkan Union Oncol
Impact of epoetin beta on quality of life in patients with malignant disease
Br J Cancer
Recombinant human erythropoietin treatment in platinum-associated anemia: A randomized, double-blind trial with placebo
J Clin Oncol
The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy
Int J Clin Lab Res
Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
J Clin Oncol
Cited by (108)
A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia
2018, Critical Reviews in Oncology/HematologyCitation Excerpt :No significant difference in HRQoL improvement between epoetin and darbepoetin was reported in the identified SLRs (Minton et al., 2008; Ross et al., 2006; Tonelli et al., 2009; Wilson et al., 2007). Ross et al. (2006) reviewed 40 studies and indicated that no clear superiority of one agent over the other could be established for transfusions and HRQoL outcomes in patients with CIA. Thirteen SLRs evaluated the safety of ESAs in patients with CKD-IA (Alsalimy and Awaisu, 2014; Vinhas et al., 2012; Phrommintikul et al., 2007; Strippoli et al., 2004; Hahn et al., 2017; Cody and Hodson, 2016; Covic et al., 2014; Koulouridis et al., 2013; Marin et al., 2014; Palmer et al., 2010; Saglimbene et al., 2017; Wilhelm-Leen and Winkelmayer, 2015; Tonelli et al., 2008b).
Erythropoietin and Nonhematopoietic Effects
2017, American Journal of the Medical SciencesCitation Excerpt :EPO is used for the treatment of anemia associated with chronic renal failure and chemotherapy.2,3 Several well-established studies have shown that in adults, the kidney is the main source of the circulating EPO, where this hormone is responsible for maintaining the red blood cell mass.4,5 EPO prevents programmed cell death (apoptosis) of erythrocyte precursors.6,7
Erythropoietin, chronic renal failure and cancer
2016, Medicina ClinicaUpdate on erythropoiesis-stimulating agents
2013, Best Practice and Research: Clinical AnaesthesiologyCitation Excerpt :The risks of death or cardiovascular events were also associated with a poor initial haematopoietic response, as doses of ESAs were escalated to meet target Hgb levels.18 Literature reviews and meta-analyses of clinical trials of ESA therapy both in approved settings and in off-label clinical trial designs have analysed survival and other safety outcomes.11,22,29–35 Overall, three meta-analyses31,32,34 indicated increased risk of mortality with the use of ESA, whereas two33,35 indicated that ESA did not significantly affect mortality.